Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Found 29628 matches for

The first patient has now been registered to the ATOM trial, a single-centre (Churchill Hospital, Oxford University Hospitals Trust) pre-operative window of opportunity study of the effects of atovaquone on hypoxia in non-small cell lung carcinoma (NSCLC).

Find out more about

Our Groups, Centres and Units

Our Research Themes

Our Clinical Trials

Our Programme Grants

Similar stories